Enodia Therapeutics is a privately held biotechnology company based in Paris, France, developing small-molecule therapies that target disease-driving proteins at the point of synthesis. Its platform selectively modulates the Sec61 translocon to promote early degradation of secreted and membrane proteins, with an initial focus on inflammatory and autoimmune diseases. Founded in 2025, Enodia was built by Argobio Studio on research originating at Institut Pasteur. The company combines proteomics, structural biology and machine-learning-guided drug design to advance its therapeutic programs. Learn more at https://www.enodiatx.com/.